Cite
HARVARD Citation
Alten, R. et al. (2013). SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data. Annals of the rheumatic diseases. p. A624. [Online].